Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

Itovebi — also known as inavolisib — is designed to be given with drugs from Pfizer Inc. and AstraZeneca plc to treat adults ...

Some of the soundbite health care policy proposals that candidates bring up for short-term political impact could in practice ...

Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Genentech, a member of the Roche (RHHBY), announced topline one-year results from the open-label, single-arm Phase IV ...

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...

Genentech, a member of the Roche Group, has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of ...

Swiss drug makers Lonza and Roche agreed in March to the sale the Vacaville campus in the heart of Solano County’s burgeoning ...